Telix Partners with Leaders in Ablative Technologies for Prostate Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Source: Globenewswire
- Partnership Formation: Telix has entered into letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided ablative technologies for prostate cancer treatment, reflecting Telix's commitment to integrating molecular imaging into clinical practices.
- Technology Application Exploration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with robotic high-intensity focused ultrasound (HIFU) and other treatment methods, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: Telix and its partners will work together to generate clinical evidence supporting best practices for prostate whole-gland, partial-gland, and focal ablation workflows, promoting the adoption of PSMA-PET imaging and enhancing personalized care.
- Precision Medicine Strategy: The CEO of Telix emphasized that as disruptive technologies continue to evolve, PSMA-PET imaging will play a crucial role in minimally invasive and image-guided treatments, driving collaborations with industry leaders to achieve personalized patient care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EDAP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EDAP
Wall Street analysts forecast EDAP stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.200
Low
2.50
Averages
8.25
High
14.00
Current: 4.200
Low
2.50
Averages
8.25
High
14.00
About EDAP
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EDAP Rebrands to FocalTherics, Emphasizing Robotic Therapy Focus
- Corporate Rebranding: EDAP TMS S.A. has announced its rebranding to FocalTherics to emphasize its exclusive focus on high-growth robotic focal therapy, which is expected to enhance brand recognition and attract more investor interest.
- Ticker Symbol Change: The company will change its Nasdaq ticker symbol from 'EDAP' to 'FOCL' effective June 1, 2026, aiming to strengthen the connection between the company and its new brand identity, thereby improving its market image.
- Financial Restructuring: FocalTherics plans to classify its non-core Extracorporeal Shock Wave Lithotripsy (ESWL) and distribution segments as discontinued operations, which is expected to simplify financial reporting and concentrate resources on core operations, enhancing profitability.
- Investor Day Event: The company will hold an Investor Day on June 1, 2026, to showcase its new corporate identity and long-term strategy, which is anticipated to bolster investor confidence in the company's future growth potential.
See More
EDAP TMS to Present at Jefferies 2026 Global Healthcare Conference
- Conference Details: EDAP TMS SA's CEO Ryan Rhodes is scheduled to present at the Jefferies 2026 Global Healthcare Conference in New York on June 4, 2026, alongside CFO Ken Mobeck for 1x1 investor meetings, showcasing the company's leadership in robotic energy-based therapies.
- Timing and Format: The event is set for 2:00-2:30 PM ET, featuring a presentation and one-on-one meetings aimed at attracting investor interest in the company's future developments, thereby enhancing market awareness.
- Technological Edge: EDAP TMS focuses on developing and distributing minimally invasive medical devices using ultrasound technology, with its Focal One® system widely used in Europe and the U.S. for prostate focal therapy, demonstrating potential for expansion into multiple indications, thus strengthening its market competitiveness.
- Investor Relations: The company ensures investors can access the presentation through live and archived webcasts, enhancing communication and transparency with investors to build trust and engagement.
See More
Telix Partners with Leaders in Ablative Technologies for Prostate Cancer
- Partnership Formation: Telix has entered into letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided ablative technologies for prostate cancer treatment, reflecting Telix's commitment to integrating molecular imaging into clinical practices.
- Technology Application Exploration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with robotic high-intensity focused ultrasound (HIFU) and other treatment methods, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: Telix and its partners will work together to generate clinical evidence supporting best practices for prostate whole-gland, partial-gland, and focal ablation workflows, promoting the adoption of PSMA-PET imaging and enhancing personalized care.
- Precision Medicine Strategy: The CEO of Telix emphasized that as disruptive technologies continue to evolve, PSMA-PET imaging will play a crucial role in minimally invasive and image-guided treatments, driving collaborations with industry leaders to achieve personalized patient care.
See More
Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
- Partnership Formation: Telix has signed letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided technologies for prostate cancer treatment, marking a strategic expansion in the prostate cancer treatment landscape.
- Technology Integration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with high-intensity focused ultrasound (HIFU) and other treatment modalities, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: The partnership will focus on generating clinical evidence to support the establishment of best practices, which is expected to accelerate the adoption of PSMA-PET imaging technology in prostate cancer treatment and promote the development of personalized medicine.
- Market Leadership: Telix's CEO emphasized that as minimally invasive technologies continue to evolve, the importance of PSMA-PET imaging in clinical decision-making is increasingly significant, and this collaboration will further solidify Telix's leadership position in the prostate cancer treatment market.
See More
EDAP TMS S.A. Reports Record Q1 2026 Earnings Driven by HIFU Sales
- Record Revenue: EDAP TMS S.A. reported total revenue of $17.8 million for Q1 2026, exceeding analysts' expectations of $16.6 million, primarily driven by Focal One robotic HIFU sales reaching $11.6 million, demonstrating the company's successful shift to higher-margin business segments.
- Multi-Site Expansion: The company has now seen 11 U.S. hospitals and health networks invest in and launch two or more Focal One robotic HIFU programs, indicating a significant increase in market penetration that is expected to further drive future revenue growth.
- International Momentum: Following the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure, EDAP achieved its first cash sale in France, marking a pivotal expansion in its global operations and revenue diversification.
- Stable Financial Outlook: The company reiterated its 2026 core HIFU revenue guidance of $50 million to $54 million, representing a 34% to 45% year-over-year growth, while also securing approximately $14 million from the European Investment Bank credit facility at the end of Q1, enhancing its financial flexibility.
See More
EDAP TMS S.A. Q1 Earnings Highlights
- Earnings Performance: EDAP TMS S.A. reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.01, while revenue reached $17.81 million, reflecting a 24.5% year-over-year increase and exceeding estimates by $1.21 million, indicating strong revenue growth momentum.
- HIFU Revenue Growth: The company experienced a 78% year-over-year increase in HIFU revenue for Q1, demonstrating sustained market demand for this business line and reinforcing its position in the high-intensity focused ultrasound treatment sector.
- U.S. HIFU Procedures Growth: There was a 53% year-over-year growth in U.S. HIFU procedures in Q1, showcasing the effectiveness of the company's expansion strategy in the U.S. market, which is expected to drive future revenue growth.
- Future Outlook: The company reiterated its revenue guidance, projecting core HIFU business revenue to be between $50 million and $54 million, representing a year-over-year growth of 34% to 45%, while non-core business revenue is expected to range from $22 million to $26 million, reflecting confidence in future growth prospects.
See More
EDAP Rebrands to FocalTherics, Emphasizing Robotic Therapy Focus
- Corporate Rebranding: EDAP TMS S.A. has announced its rebranding to FocalTherics to emphasize its exclusive focus on high-growth robotic focal therapy, which is expected to enhance brand recognition and attract more investor interest.
- Ticker Symbol Change: The company will change its Nasdaq ticker symbol from 'EDAP' to 'FOCL' effective June 1, 2026, aiming to strengthen the connection between the company and its new brand identity, thereby improving its market image.
- Financial Restructuring: FocalTherics plans to classify its non-core Extracorporeal Shock Wave Lithotripsy (ESWL) and distribution segments as discontinued operations, which is expected to simplify financial reporting and concentrate resources on core operations, enhancing profitability.
- Investor Day Event: The company will hold an Investor Day on June 1, 2026, to showcase its new corporate identity and long-term strategy, which is anticipated to bolster investor confidence in the company's future growth potential.
See More
EDAP TMS to Present at Jefferies 2026 Global Healthcare Conference
- Conference Details: EDAP TMS SA's CEO Ryan Rhodes is scheduled to present at the Jefferies 2026 Global Healthcare Conference in New York on June 4, 2026, alongside CFO Ken Mobeck for 1x1 investor meetings, showcasing the company's leadership in robotic energy-based therapies.
- Timing and Format: The event is set for 2:00-2:30 PM ET, featuring a presentation and one-on-one meetings aimed at attracting investor interest in the company's future developments, thereby enhancing market awareness.
- Technological Edge: EDAP TMS focuses on developing and distributing minimally invasive medical devices using ultrasound technology, with its Focal One® system widely used in Europe and the U.S. for prostate focal therapy, demonstrating potential for expansion into multiple indications, thus strengthening its market competitiveness.
- Investor Relations: The company ensures investors can access the presentation through live and archived webcasts, enhancing communication and transparency with investors to build trust and engagement.
See More
Telix Partners with Leaders in Ablative Technologies for Prostate Cancer
- Partnership Formation: Telix has entered into letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided ablative technologies for prostate cancer treatment, reflecting Telix's commitment to integrating molecular imaging into clinical practices.
- Technology Application Exploration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with robotic high-intensity focused ultrasound (HIFU) and other treatment methods, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: Telix and its partners will work together to generate clinical evidence supporting best practices for prostate whole-gland, partial-gland, and focal ablation workflows, promoting the adoption of PSMA-PET imaging and enhancing personalized care.
- Precision Medicine Strategy: The CEO of Telix emphasized that as disruptive technologies continue to evolve, PSMA-PET imaging will play a crucial role in minimally invasive and image-guided treatments, driving collaborations with industry leaders to achieve personalized patient care.
See More
Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
- Partnership Formation: Telix has signed letters of intent with EDAP TMS and Profound Medical to develop advanced minimally invasive and image-guided technologies for prostate cancer treatment, marking a strategic expansion in the prostate cancer treatment landscape.
- Technology Integration: The collaboration will explore the integration of Telix's PSMA-PET imaging agents with high-intensity focused ultrasound (HIFU) and other treatment modalities, aiming to optimize treatment efficacy while minimizing side effects, thereby enhancing patient experience.
- Clinical Evidence Generation: The partnership will focus on generating clinical evidence to support the establishment of best practices, which is expected to accelerate the adoption of PSMA-PET imaging technology in prostate cancer treatment and promote the development of personalized medicine.
- Market Leadership: Telix's CEO emphasized that as minimally invasive technologies continue to evolve, the importance of PSMA-PET imaging in clinical decision-making is increasingly significant, and this collaboration will further solidify Telix's leadership position in the prostate cancer treatment market.
See More
EDAP TMS S.A. Reports Record Q1 2026 Earnings Driven by HIFU Sales
- Record Revenue: EDAP TMS S.A. reported total revenue of $17.8 million for Q1 2026, exceeding analysts' expectations of $16.6 million, primarily driven by Focal One robotic HIFU sales reaching $11.6 million, demonstrating the company's successful shift to higher-margin business segments.
- Multi-Site Expansion: The company has now seen 11 U.S. hospitals and health networks invest in and launch two or more Focal One robotic HIFU programs, indicating a significant increase in market penetration that is expected to further drive future revenue growth.
- International Momentum: Following the French National Health System's decision to provide universal coverage for the Focal One HIFU procedure, EDAP achieved its first cash sale in France, marking a pivotal expansion in its global operations and revenue diversification.
- Stable Financial Outlook: The company reiterated its 2026 core HIFU revenue guidance of $50 million to $54 million, representing a 34% to 45% year-over-year growth, while also securing approximately $14 million from the European Investment Bank credit facility at the end of Q1, enhancing its financial flexibility.
See More
EDAP TMS S.A. Q1 Earnings Highlights
- Earnings Performance: EDAP TMS S.A. reported a Q1 GAAP EPS of -$0.24, missing expectations by $0.01, while revenue reached $17.81 million, reflecting a 24.5% year-over-year increase and exceeding estimates by $1.21 million, indicating strong revenue growth momentum.
- HIFU Revenue Growth: The company experienced a 78% year-over-year increase in HIFU revenue for Q1, demonstrating sustained market demand for this business line and reinforcing its position in the high-intensity focused ultrasound treatment sector.
- U.S. HIFU Procedures Growth: There was a 53% year-over-year growth in U.S. HIFU procedures in Q1, showcasing the effectiveness of the company's expansion strategy in the U.S. market, which is expected to drive future revenue growth.
- Future Outlook: The company reiterated its revenue guidance, projecting core HIFU business revenue to be between $50 million and $54 million, representing a year-over-year growth of 34% to 45%, while non-core business revenue is expected to range from $22 million to $26 million, reflecting confidence in future growth prospects.
See More
